proof 301: infigratinib in advanced cca
Published 4 years ago • 131 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
4:28
proof: infigratinib as first-line therapy in patients with advanced cca
-
1:15
infigratinib in previously treated advanced cca
-
2:31
efficacy of second-line chemotherapy in advanced cca with fgfr2 fusions
-
7:27
infigratinib for cca
-
1:16
dr. abou-alfa on remaining questions with infigratinib in fgfr2 cholangiocarcinoma
-
11:05
3mensio ct pre-case planning: tavr with alternate access (axillary/subclavian)
-
2:40
caval valve implantation (cavi): procedural planning in a complex case
-
11:11
3mensio ct pre-case planning: tavr with high coronary obstruction risk
-
4:51
natural history of patients with advanced cca with fgfr2 gene alterations or wild-type fgfr2
-
4:12
fgfr2 inhibitors in advanced cholangiocarcinoma
-
1:00:01
webinar: targeting the fgfr pathway: infigratinib in cholangiocarcinoma
-
20:52
preoperative optimization and eras in mie for scc stricture: case 2 - suzanne gisbertz
-
6:50
visually estimated resolve score based on ctca to predict sb occlusion....... - dr kajetan grodecki
-
7:31
fgfr inhibition in advanced cca
-
2:17
dr. roychowdhury on fgfr inhibitor infigratinib in cholangiocarcinoma
-
17:18
insights from step-hfpef trial | esc heart failure 2024
-
1:34
advanced cholangiocarcinoma: fgfr2 inhibitors vs chemo
-
1:00
exploring folfiri and checkpoint inhibitors in gastric adenocarcinoma
-
1:36
liquid biopsies and tumor-informed ctdna profiling in metastatic urothelial carcinoma
-
8:32
clinical approach to multi-vessel cad
-
5:09
comparison of philips vessel navigator and cydar medical fusion systems.